128 related articles for article (PubMed ID: 33823990)
41. Body weight and risk of breast cancer in BRCA1/2 mutation carriers.
Manders P; Pijpe A; Hooning MJ; Kluijt I; Vasen HF; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer H; Ausems MG; van Os TA; Gomez-Garcia EB; Brohet RM; ; van Leeuwen FE; Rookus MA
Breast Cancer Res Treat; 2011 Feb; 126(1):193-202. PubMed ID: 20730487
[TBL] [Abstract][Full Text] [Related]
42. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
[TBL] [Abstract][Full Text] [Related]
43. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
[TBL] [Abstract][Full Text] [Related]
44. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
45. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
46. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
47. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Xia YY; Gronwald J; Karlan B; Lubinski J; McCuaig JM; Brooks J; Moller P; Eisen A; Sun S; Senter L; Bordeleau L; Neuhausen SL; Singer CF; Tung N; Foulkes WD; Sun P; Narod SA; Kotsopoulos J;
Gynecol Oncol; 2022 Mar; 164(3):514-521. PubMed ID: 35063280
[TBL] [Abstract][Full Text] [Related]
48. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
49. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
Brohet RM; Goldgar DE; Easton DF; Antoniou AC; Andrieu N; Chang-Claude J; Peock S; Eeles RA; Cook M; Chu C; Noguès C; Lasset C; Berthet P; Meijers-Heijboer H; Gerdes AM; Olsson H; Caldes T; van Leeuwen FE; Rookus MA
J Clin Oncol; 2007 Sep; 25(25):3831-6. PubMed ID: 17635951
[TBL] [Abstract][Full Text] [Related]
50. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
Kotsopoulos J; Lubinski J; Moller P; Lynch HT; Singer CF; Eng C; Neuhausen SL; Karlan B; Kim-Sing C; Huzarski T; Gronwald J; McCuaig J; Senter L; Tung N; Ghadirian P; Eisen A; Gilchrist D; Blum JL; Zakalik D; Pal T; Sun P; Narod SA;
Breast Cancer Res Treat; 2014 Feb; 143(3):579-86. PubMed ID: 24458845
[TBL] [Abstract][Full Text] [Related]
51. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ
Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855
[TBL] [Abstract][Full Text] [Related]
52. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD.
Derks-Smeets IAP; van Tilborg TC; van Montfoort A; Smits L; Torrance HL; Meijer-Hoogeveen M; Broekmans F; Dreesen JCFM; Paulussen ADC; Tjan-Heijnen VCG; Homminga I; van den Berg MMJ; Ausems MGEM; de Rycke M; de Die-Smulders CEM; Verpoest W; van Golde R
J Assist Reprod Genet; 2017 Nov; 34(11):1475-1482. PubMed ID: 28831696
[TBL] [Abstract][Full Text] [Related]
53. Assessment of ovarian reserve and reproductive outcomes in
Ponce J; Fernandez-Gonzalez S; Calvo I; Climent M; Peñafiel J; Feliubadaló L; Teulé A; Lázaro C; Brunet JM; Candás-Estébanez B; Durán Retamal M
Int J Gynecol Cancer; 2020 Jan; 30(1):83-88. PubMed ID: 31780568
[TBL] [Abstract][Full Text] [Related]
54. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
55. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
[TBL] [Abstract][Full Text] [Related]
56. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
57. Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis.
Liu X; Yue J; Pervaiz R; Zhang H; Wang L
Front Endocrinol (Lausanne); 2022; 13():986477. PubMed ID: 36176466
[TBL] [Abstract][Full Text] [Related]
58. The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
Bernstein-Molho R; Laitman Y; Schayek H; Reish O; Lotan S; Haim S; Zidan J; Friedman E
Breast Cancer Res Treat; 2018 Feb; 167(3):697-702. PubMed ID: 29086229
[TBL] [Abstract][Full Text] [Related]
59. FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns.
Laitman Y; Ries-Levavi L; Berkensdadt M; Korach J; Perri T; Pras E; Friedman E
Genet Res (Camb); 2014 Oct; 96():e11. PubMed ID: 25579682
[TBL] [Abstract][Full Text] [Related]
60. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]